Sun Radiopharmaceuticals

Sun Radiopharmaceuticals is the specialized nuclear medicine division of Sun Pharmaceutical Industries Ltd., a global leader in generic pharmaceuticals. The company focuses on the development, manufacturing, and commercialization of radiopharmaceutical products used primarily in diagnostic imaging. Its portfolio includes the Technetium-99m generator and a variety of cold kits for bone, renal, and cardiac imaging, as well as therapeutic agents like Sodium Iodide I-131. Operating from a dedicated facility in Billerica, Massachusetts, the division was significantly bolstered by the 2014 acquisition of Pharmalucence. Sun Radiopharmaceuticals provides essential diagnostic tools to hospitals and radiopharmacies, supporting critical patient care in oncology and cardiology.